Arcturus Therapeutics (ARCT) versus Its Peers Critical Review

Arcturus Therapeutics (NASDAQ: ARCT) is one of 287 publicly-traded companies in the “Bio Therapeutic Drugs” industry, but how does it compare to its rivals? We will compare Arcturus Therapeutics to similar businesses based on the strength of its dividends, institutional ownership, analyst recommendations, valuation, risk, earnings and profitability.

Analyst Recommendations

This is a summary of current recommendations and price targets for Arcturus Therapeutics and its rivals, as provided by

Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score
Arcturus Therapeutics 0 6 2 0 2.25
Arcturus Therapeutics Competitors 938 3386 11889 239 2.69

Arcturus Therapeutics presently has a consensus target price of $1.54, indicating a potential downside of 83.39%. As a group, “Bio Therapeutic Drugs” companies have a potential upside of 41.86%. Given Arcturus Therapeutics’ rivals stronger consensus rating and higher possible upside, analysts plainly believe Arcturus Therapeutics has less favorable growth aspects than its rivals.

Earnings and Valuation

This table compares Arcturus Therapeutics and its rivals revenue, earnings per share and valuation.

Gross Revenue Net Income Price/Earnings Ratio
Arcturus Therapeutics N/A -$24.60 million -1.74
Arcturus Therapeutics Competitors $290.27 million $35.99 million 54.07

Arcturus Therapeutics’ rivals have higher revenue and earnings than Arcturus Therapeutics. Arcturus Therapeutics is trading at a lower price-to-earnings ratio than its rivals, indicating that it is currently more affordable than other companies in its industry.

Volatility and Risk

Arcturus Therapeutics has a beta of 1.54, indicating that its share price is 54% more volatile than the S&P 500. Comparatively, Arcturus Therapeutics’ rivals have a beta of 2.48, indicating that their average share price is 148% more volatile than the S&P 500.

Institutional & Insider Ownership

49.8% of shares of all “Bio Therapeutic Drugs” companies are held by institutional investors. 16.8% of shares of all “Bio Therapeutic Drugs” companies are held by company insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a stock is poised for long-term growth.


This table compares Arcturus Therapeutics and its rivals’ net margins, return on equity and return on assets.

Net Margins Return on Equity Return on Assets
Arcturus Therapeutics N/A -36.83% -34.70%
Arcturus Therapeutics Competitors -5,383.23% -82.24% -35.15%


Arcturus Therapeutics rivals beat Arcturus Therapeutics on 10 of the 13 factors compared.

About Arcturus Therapeutics

Arcturus Therapeutics Ltd, formerly Alcobra Ltd, is an Israel-based preclinical-stage biopharmaceutical company primarily focused on the discovery, development and commercialization of ribonucleic acid (RNA) medicines using lipid-mediated nanoparticle delivery system (LUNAR) and Unlocked Nucleomonomer Agent (UNA) Oligomer chemistry technology platforms. The Company, through Arcturus Therapeutics Inc, its wholly owned subsidiary based in the United States, is focused on developing RNA medicines for rare, infectious, fibrotic and respiratory diseases with unmet medical needs, including cystic fibrosis, nonalcoholic steatohepatitis (NASH) and rare liver diseases, as well as replicon RNA vaccines.

Receive News & Ratings for Arcturus Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Arcturus Therapeutics and related companies with's FREE daily email newsletter.

Latest News

Leave a Reply